Mirum Pharmaceuticals, Inc. (MIRM)

Mirum Pharmaceuticals' stock price increased by 81.18% between January 6, 2025, and January 2, 2026, and by 92.63% over the past year. Key events include strong preliminary 2025 results and an optimistic 2026 outlook, achieving positive cash flow from operations in 2025, advancements in clinical programs for Volixibat and LIVMARLI, the proposed acquisition of Bluejay Therapeutics, an insider stock sale by a director, positive analyst ratings and price target increases, and inducement grants to new employees.

Specific data on demand seasonality for Mirum Pharmaceuticals' products is not explicitly provided. While tools exist to identify seasonal patterns in its stock performance, the nature of rare disease medications typically implies consistent demand driven by patient need rather than seasonal fluctuations.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for rare and life-threatening diseases, particularly cholestatic and rare liver diseases, as well as select genetic and metabolic disorders. Its commercial portfolio includes LIVMARLI (maralixibat) for cholestatic pruritus in ALGS and PFIC, CHOLBAM (cholic acid) for bile-acid synthesis disorders and peroxisomal disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX) and cholestasis inborn errors of bile acid metabolism. The company's pipeline includes Volixibat for PSC and PBC, MRM-3379 for Fragile X syndrome (FXS), and Brelovitug for chronic hepatitis delta virus (HDV), pending the acquisition of Bluejay Therapeutics.

Mirum Pharmaceuticals is headquartered in Foster City, California, and primarily operates in the United States. The company is expanding globally, aiming for commercial access in 33 countries by the end of 2025. LIVMARLI is approved in the U.S., Europe, and Japan for Alagille syndrome and progressive familial intrahepatic cholestasis.

Mirum Pharmaceuticals maintains a positive brand reputation through its patient-centric approach and dedication to addressing unmet medical needs in rare diseases. The company focuses on developing innovative therapies for rare and orphan diseases, particularly rare liver conditions, which contributes to its strong standing within the rare disease community. No negative events affecting the brand were reported in the past year.

Mirum Pharmaceuticals, Inc. is primarily owned by institutional shareholders, who hold 111.58% of the stock, and Mirum Pharmaceuticals insiders, who hold 101.54%. Retail investors hold 0.00%. Major institutional owners include Frazier Life Sciences Management, L.P., Janus Henderson Group Plc, BlackRock, Inc., Vanguard Group Inc, Eventide Asset Management, Llc, BVF Inc/il, State Street Corp and Price T Rowe Associates Inc /md/. The largest individual shareholder is Joshua Makower, who owns 4.19 million shares, representing 8.15% of the company.